Clinical benefits and potential risks of adalimumab in non-JIA chronic paediatric uveitis.

ABSTRACT:

Purpose

To describe the treatment results with adalimumab in chronic paediatric uveitis, not associated with juvenile idiopathic arthritis (JIA).

Methods

Medical records of children with non-JIA-uveitis were reviewed retrospectively. Children without an underlying systemic disease were pre-screened with brain magnetic resonance imaging (MRI) to exclude white matter abnormalities/demyelination.

Results

Twenty-six patients were pre-screened with brain MRI, of whom adalimumab was contraindicated in six patients (23%) with non-anterior uveitis. Forty-three patients (81 eyes) were included. Disease inactivity was achieved in 91% of the patients after a median of three months (3-33). Best-corrected visual acuity (BCVA) improved from 0.16 ± 0.55 logarithm of the minimum angl

SUBMITTER: Kouwenberg CV 

PROVIDER: S-EPMC9290889 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature